These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 17323498)

  • 21. Imatinib: as adjuvant therapy for gastrointestinal stromal tumor†: profile report.
    Sanford M; Scott LJ
    BioDrugs; 2011 Jun; 25(3):191-2. PubMed ID: 21627342
    [No Abstract]   [Full Text] [Related]  

  • 22. [Carney triad: clinicopathologic study of 2 cases with molecular analysis].
    Xu C; Hou YY; Qi WD; Lu SH; Hou J; Tan YS; Qin J; Sun YH
    Zhonghua Bing Li Xue Za Zhi; 2009 Sep; 38(9):626-7. PubMed ID: 20079194
    [No Abstract]   [Full Text] [Related]  

  • 23. Gastro-intestinal stromal tumours: a review of current management options.
    Loong HH
    Hong Kong Med J; 2007 Feb; 13(1):61-5. PubMed ID: 17277393
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhaled tyrosine kinase inhibitors for pulmonary hypertension: a possible future treatment.
    Pitsiou G; Zarogoulidis P; Petridis D; Kioumis I; Lampaki S; Organtzis J; Porpodis K; Papaiwannou A; Tsiouda T; Hohenforst-Schmidt W; Kakolyris S; Syrigos K; Huang H; Li Q; Turner JF; Zarogoulidis K
    Drug Des Devel Ther; 2014; 8():1753-63. PubMed ID: 25336919
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [KIT mutation analysis in pathological diagnosis and target-therapy of gastrointestinal stromal tumors: an update].
    Chen LR
    Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):440-3. PubMed ID: 17845754
    [No Abstract]   [Full Text] [Related]  

  • 26. STI-stop transplanting immediately?
    Klingemann HG
    J Hematother Stem Cell Res; 2002 Apr; 11(2):165-7. PubMed ID: 11983089
    [No Abstract]   [Full Text] [Related]  

  • 27. Effectiveness of imatinib therapy for sickle cell anemia and chronic myeloid leukemia.
    Murphy M; Close J; Lottenberg R; Rajasekhar A
    Am J Med Sci; 2014 Mar; 347(3):254-5. PubMed ID: 24553361
    [No Abstract]   [Full Text] [Related]  

  • 28. Investigator profile. Brian J. Druker, M.D. Interview by Vicki P. Glaser.
    Druker BJ
    J Hematother Stem Cell Res; 2001 Dec; 10(6):721-4. PubMed ID: 11798498
    [No Abstract]   [Full Text] [Related]  

  • 29. Cancer drugs. Smart weapons prove tough to design.
    Couzin J
    Science; 2002 Oct; 298(5593):522-5. PubMed ID: 12386312
    [No Abstract]   [Full Text] [Related]  

  • 30. Imatinib mesylate treatment for a Chinese patient with metastatic and recurrent dermatofibrosarcoma protuberans: is sustained partial remission possible?
    Wang C; Luo Z; Zheng B; Chen Y; Cao X; Wang J; Zhang R; Shi Y
    Eur J Cancer Prev; 2012 Nov; 21(6):585-7. PubMed ID: 23014697
    [No Abstract]   [Full Text] [Related]  

  • 31. [Molecular targeting in the treatment of lung cancer--toward the development of individualized treatment].
    Sone S; Kakiuchi S; Yano S
    Nihon Naika Gakkai Zasshi; 2004 Sep; 93(9):1963-70. PubMed ID: 15515691
    [No Abstract]   [Full Text] [Related]  

  • 32. Desmoid-type fibromatosis.
    Bertucci F; Gonçalves A; Viens P; Monges G; Dubreuil P
    J Neurosurg; 2007 Aug; 107(2):473-5; author reply 475. PubMed ID: 17695408
    [No Abstract]   [Full Text] [Related]  

  • 33. Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations.
    Wardelmann E; Thomas N; Merkelbach-Bruse S; Pauls K; Speidel N; Büttner R; Bihl H; Leutner CC; Heinicke T; Hohenberger P
    Lancet Oncol; 2005 Apr; 6(4):249-51. PubMed ID: 15811621
    [No Abstract]   [Full Text] [Related]  

  • 34. Imatinib mesylate inhibits the growth of metastatic lung lesions in a patient with dermatofibrosarcoma protuberans.
    Mizutani K; Tamada Y; Hara K; Tsuzuki T; Saeki H; Tamaki K; Matsumoto Y
    Br J Dermatol; 2004 Jul; 151(1):235-7. PubMed ID: 15270901
    [No Abstract]   [Full Text] [Related]  

  • 35. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a Phase II clinical trial.
    Altundag O; Altundag K; Boruban C; Silay YS; Turen S
    Cancer; 2005 Nov; 104(9):2033-4; author reply 2034. PubMed ID: 16161057
    [No Abstract]   [Full Text] [Related]  

  • 36. Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs.
    Isotani M; Ishida N; Tominaga M; Tamura K; Yagihara H; Ochi S; Kato R; Kobayashi T; Fujita M; Fujino Y; Setoguchi A; Ono K; Washizu T; Bonkobara M
    J Vet Intern Med; 2008; 22(4):985-8. PubMed ID: 18564222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Update on the use of imatinib mesylate.
    Sawyers CL
    Clin Adv Hematol Oncol; 2005 Oct; 3(10):757-8. PubMed ID: 16258483
    [No Abstract]   [Full Text] [Related]  

  • 38. Small-cell lung cancer in never-smokers: a case series with information on family history of cancer and environmental tobacco smoke.
    Kurahara Y; Kawaguchi T; Tachibana K; Atagi S; Hayashi S; Kitaichi M; Ou SH; Takada M
    Clin Lung Cancer; 2012 Jan; 13(1):75-9. PubMed ID: 21729654
    [No Abstract]   [Full Text] [Related]  

  • 39. Simultaneous targeting of P-gp and XIAP with siRNAs increases sensitivity of P-gp overexpressing CML cells to imatinib.
    Seca H; Lima RT; Guimarães JE; Helena Vasconcelos M
    Hematology; 2011 Mar; 16(2):100-8. PubMed ID: 21418741
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Top ten health stories of 2001.
    Harv Health Lett; 2001 Dec; 27(2):1-3. PubMed ID: 11751085
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.